Research identifies 81 new genes linked to basal-like breast cancer — Evidence Review
Published in Nature, by researchers from Sinai Health, Lunenfeld-Tanenbaum Research Institute, University of Toronto
Researched by
— the AI search engine for science
Table of Contents
A new study using advanced gene-editing in living tumors has identified 81 previously unknown genes linked to aggressive basal-like breast cancer. These findings from Sinai Health align with the broader literature on chromosomal instability and cancer gene discovery, building upon existing knowledge in this challenging cancer subtype.
- Basal-like breast cancers are well-established as highly aggressive, genetically complex, and difficult to treat, with prior studies emphasizing both their unique gene mutation profiles and the challenges of pinpointing true driver genes due to chromosomal instability 1 2 4.
- The new study's focus on aneuploidy and its direct functional gene screening in living tumors addresses limitations of past research that relied primarily on in vitro models, which often missed context-dependent cancer drivers 2 5.
- Related research consistently demonstrates that chromosomal instability accelerates tumor evolution and therapy resistance, highlighting the importance of identifying specific gene drivers as potential therapeutic targets—a theme directly supported and expanded by the new findings 6 7 10.
Study Overview and Key Findings
Basal-like breast cancer (BLBC), also known as triple-negative breast cancer, lacks the molecular targets that make other breast cancers treatable with precision therapies. High levels of chromosomal instability and aneuploidy in these tumors complicate the search for specific genes that drive cancer growth. This study addresses these challenges by deploying a novel dual-function CRISPR system in living animal models, enabling the functional assessment of thousands of genes within representative tumor environments. The approach led to the identification of 81 genes not previously linked to BLBC, providing new avenues for research and potential treatment strategies.
| Property | Value |
|---|---|
| Study Year | 2026 |
| Organization | Sinai Health, Lunenfeld-Tanenbaum Research Institute, University of Toronto |
| Journal Name | Nature |
| Authors | Khalid N. Al-Zahrani, Ellen R. Langille, Jocelyn Nurtanto, Andreea Obersterescu, Katie Teng, Christopher Lowden, Julien Dessapt, Cynthia H. Chiu, Lauren V. Caldwell, David P. Cook, Miguel A. Pérez-Castro, Jacob M. Berman, Ricky Tsai, Alexander T. Bahcheli, Geraldine Mbamalu, Shifei Wu, Masahiro Narimatsu, Adele G. Lopes, Iosifina Fotiadou, Kin Chan, Linkang Zhang, K. W. Annie Bang, Michael J. Parsons, Larissa Mourao, E. Idil Temel, Liddy McCulla, Palavalasa Sravya, Li Zhang, Peter Sajjakulnukit, Costas A. Lyssiotis, Alexander D. Borowsky, Colinda L. G. J. Scheele, Daniel R. Wahl, Hartland W. Jackson, Katherine S. Stewart, Elaine Fuchs, Sean E. Egan, Miguel Angel Pujana, Jüri Reimand, Jeffrey L. Wrana, Daniel Schramek |
| Population | Basal-like breast cancer cells |
| Sample Size | n=3700 genes |
| Methods | Animal Study |
| Outcome | Identification of cancer-causing genes |
| Results | 81 new genes associated with basal-like breast cancer were identified. |
Literature Review: Related Studies
To place these findings in context, we searched the Consensus database—which contains over 200 million research papers—using targeted queries. The following search queries were used:
- basal-like breast cancer genes
- chromosome instability cancer associations
- new gene discoveries cancer research
Below, we summarize key themes and findings from the literature, highlighting how they relate to the current study.
| Topic | Key Findings |
|---|---|
| What are the genetic and molecular characteristics of basal-like breast cancer? | - Basal-like breast cancers are aggressive, highly heterogeneous, and often lack hormone receptors, complicating treatment and classification 1 4. - Distinct mutation profiles, including BRCA1 and RB1 mutations and deletions, are common in this subtype 2. |
| How does chromosomal instability impact cancer progression and therapy resistance? | - Chromosomal instability (CIN) accelerates tumor evolution, promotes immune evasion, and contributes to poor prognosis and therapeutic resistance 6 7 9 10. - CIN underlies intratumoral heterogeneity, fueling adaptation and complicating targeted therapy 6 8 10. |
| How effective are current approaches for discovering new cancer driver genes? | - Large-scale genomic and functional studies have identified many cancer genes, but in vitro models often miss context-dependent drivers found in living systems 12 13. - The dynamic tumor microenvironment and chromosomal alterations challenge the identification of true drivers 13 14. |
| What are the implications of new gene discoveries for cancer treatment strategies? | - Identification of new cancer driver genes provides opportunities for targeted therapy, especially in cancers like BLBC that lack established treatment targets 10 12. - Understanding gene function in vivo is essential for developing effective interventions 5 12. |
What are the genetic and molecular characteristics of basal-like breast cancer?
Previous research has firmly established basal-like breast cancers as a genetically complex and aggressive subtype. They are characterized by unique mutation profiles, high heterogeneity, and the absence of traditional therapeutic targets, making them difficult to treat. The new study's identification of additional driver genes adds to the understanding of the underlying molecular landscape.
- Basal-like breast cancers are typically "triple-negative," lacking estrogen, progesterone, and HER2 receptors, which restricts treatment options 1 4.
- These tumors often harbor mutations in BRCA1, RB1, and RAS, as well as deletions of p16 and p14ARF, distinguishing them from other subtypes 2.
- The heterogeneity of gene expression and mutation patterns complicates classification and risk prediction, as highlighted in several reviews 1 4.
- The new study's focus on large-scale, in vivo functional screening helps address the need for more comprehensive discovery of subtype-specific drivers 2 4.
How does chromosomal instability impact cancer progression and therapy resistance?
Chromosomal instability (CIN) and aneuploidy are central features of many cancers, particularly basal-like subtypes. The literature indicates that CIN drives tumor evolution, increases heterogeneity, and leads to therapy resistance—challenges directly addressed by the current study's methodology.
- CIN contributes to poor prognosis, metastasis, and resistance to therapy, facilitating rapid adaptation to environmental pressures 6 7 9 10.
- Mechanistically, CIN increases genetic diversity within tumors, promoting immune evasion and complicating efforts to target cancer cells 6 8 10.
- Aneuploidy and CIN are particularly pronounced in basal-like and metaplastic breast cancers, aligning with the new study's focus 3 7.
- The study's dual-function CRISPR approach allows direct modeling of both gene loss and amplification, mirroring the effects of CIN in vivo 7 10.
How effective are current approaches for discovering new cancer driver genes?
Large-scale genomic studies have cataloged many cancer genes, yet there remain limitations—particularly in models that do not recapitulate the full tumor environment. The new study addresses this by using in vivo functional screening, which is more likely to capture context-dependent driver genes.
- High-throughput genomic analyses have identified both common and rare cancer driver genes, but often require large sample sizes for saturation 12 13.
- In vitro models sometimes fail to replicate the complexities of the tumor microenvironment, missing drivers that are only relevant in vivo 13 14.
- New technologies, such as transcriptome sequencing and CRISPR-based screening, are expanding the set of discoverable cancer genes 14.
- The current study's methodology builds on these advances by directly testing gene function in living tumors, providing a richer understanding of driver gene roles 13.
What are the implications of new gene discoveries for cancer treatment strategies?
The identification of new driver genes in basal-like breast cancer offers avenues for developing targeted therapies, particularly where existing options are limited. Insights from related studies underscore the importance of translating these discoveries into clinical interventions.
- Targeting CIN and its downstream effects is increasingly recognized as critical for overcoming drug resistance and improving outcomes in aggressive cancers 10 12.
- Context-dependent gene drivers, such as those identified in the new study, may represent novel therapeutic vulnerabilities 5 10.
- Understanding how newly discovered genes, like PLGRKT, support tumor adaptation to hypoxia or other stresses is essential for designing effective treatments 5 12.
- Continued integration of genomic, functional, and clinical data will be necessary to translate gene discoveries into precision medicine 12 13.
Future Research Questions
Despite significant advances, many questions remain about the mechanisms and therapeutic implications of chromosomal instability and gene drivers in basal-like breast cancer. Addressing these gaps will require further research combining genomic, functional, and clinical approaches.
| Research Question | Relevance |
|---|---|
| How do the newly identified driver genes in basal-like breast cancer influence tumor progression and therapy response? | Understanding the functional impact of these genes could reveal mechanisms of aggressiveness and resistance, guiding new therapeutic strategies 2 10. |
| Can targeting PLGRKT and other hypoxia-adaptive genes improve outcomes in triple-negative breast cancer? | PLGRKT's role in tumor survival under hypoxic conditions highlights a potential vulnerability; preclinical and clinical evaluation is needed 5 12. |
| What is the clinical significance of chromosomal instability levels in basal-like breast cancer patients? | Stratifying patients based on CIN may inform prognosis and guide individualized treatment, as CIN is linked to poor outcomes and resistance 9 10. |
| How do in vivo tumor microenvironments modulate the activity of cancer driver genes compared to in vitro models? | The discrepancy between in vivo and in vitro findings underscores the need to understand how the microenvironment shapes gene function and therapeutic vulnerabilities 2 13. |
| What combinatorial gene targets can be leveraged to overcome therapy resistance in chromosomally unstable breast cancers? | Combining insights from multiple cancer drivers may be required to counteract the adaptability conferred by chromosomal instability and heterogeneity 7 10. |